SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on the prolonged Iran conflict, Trumps rejection of ceasefire proposals, and uncertainty over renewed strikes, alongside concerns that Hormuz disruptions are affecting oil, diesel, and broader costs. Many criticize the wars economic and political fallout, while some defend Trumps approach or expect negotiations to continue.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is drawing attention after a sharp rally on increased volume, with traders focused on its move through key resistance and whether the momentum can hold. Bulls are cheering a possible breakout or short squeeze, while skeptics see another short-lived pop that could fade; no single confirmed news catalyst dominates the discussion.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Attention centers on Starship Flight 14s first orbital attempt and planned deployment of 26 Starlink V3 satellites, viewed by bullish traders as a test of future Starlink capacity and launch economics. Others question whether success is already priced in and cite execution risk, potential sell-the-news pressure, and insider share sales.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius federal grant to retrofit a U.S. battery production line for high-energy drone cells is the main catalyst drawing attention. Many traders view it as validation of defense demand and a path to greater production capacity, while others note that funding is conditional and the shares have struggled to sustain gains amid calls for stronger orders and execution.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is drawing attention amid a sharp Treasury selloff and elevated yields, with traders citing hawkish Fed expectations, resilient economic data, oil-driven inflation risks and concerns about government debt and bond supply. Most discussion is bearish on long-duration bonds, though some traders see the decline as a buying opportunity or anticipate a reversal.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silvers pullback and volatile trading dominate discussion, with traders pointing to rising Treasury yields, a stronger dollar and rate-hike concerns amid oil- and Iran-related inflation worries. Many are frustrated or wary of further losses, while others are buying the dip and citing tight supply, industrial demand and currency-debasement concerns as reasons for a bullish long-term view.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK results in wet age-related macular degeneration are the focus: traders report that Zenkuda and KSI-501 met primary endpoints and were non-inferior to aflibercept, with many reacting positively. The readout has also fueled debate over how durable or commercially competitive the results are and expectations of volatile trading around the biotech catalyst.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

ALGOs sharp rebound has traders focused on a possible technical turnaround, with bullish posts pointing to improving chart momentum and broader altcoin strength. Others question whether the move can hold, citing the tokens history of fading rallies and continued long-term losses.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is under pressure as rising Treasury yields and expectations for further Fed rate hikes weigh on non-yielding gold, with oil-driven inflation adding to rate concerns despite geopolitical tensions. Traders are divided between viewing the drop as a buying opportunity and warning that the selloff could deepen.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as shifting USIran ceasefire and negotiation headlines keep the Strait of Hormuzs oil flows and supply risks in focus. Traders are split between expecting continued disruption to support oil and viewing a possible deal or end to the conflict as a reason for the geopolitical premium to unwind; repeated reversals have fueled debate over headline-driven volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Equity

Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.


Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential momentum warnings for healthcare investors.read more...

HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62  

TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.


Helus Pharma Appoints Michael Halstead CEO, Effective Immediately

(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately...

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs 

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.


A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time PR Newswire NEW YORK, July 17, 2026 Issued on...

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.71	--	--	N/A
Q1 '26	-$0.85	-$0.91	-7.47%	MISSED
Q4 '25	-$0.83	--	--	N/A
Q3 '25	-$0.76	-$1.00	-31.58%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

HELP Earnings

Upcoming Earnings: Q2 '26

Historical Earnings